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ABSTRACT 
 
Rationale: Ischemic stroke (IS) is among the leading causes of adult disability. Part of the variability in 
functional outcome after stroke has been attributed to genetic factors but no locus has been consistently 
associated with stroke outcome. 
 
Objective: Our aim was to identify genetic loci influencing the recovery process using accurate 
phenotyping to produce the largest genome-wide association study (GWAS) in IS recovery to date. 
 
Methods and Results: A 12-cohort, two-phase (discovery-replication and joint) meta-analysis of GWAS 
included anterior-territory and previously independent IS cases. Functional outcome was recorded using 
3-month modified Rankin Scale (mRS). Analyses were adjusted for confounders such as discharge 
NIHSS. A gene-based burden test was performed. The discovery phase (n=1,225) was followed by open 
(n=2,482) and stringent joint-analyses (n=1,791). Those cohorts with mRS recorded at timepoints other 
than 3-month or incomplete data on previous functional status were excluded in the stringent analyses. 
Novel variants in PATJ gene were associated with worse functional outcome at 3-month after stroke. The 
top variant was rs76221407 (G allele, beta=0·40, p=1·70x10-9). 
 
Conclusions: Our results identify a set of common variants in PATJ gene associated with 3-month 
functional outcome at genome-wide significance level. Future studies should examine the role of PATJ in 
stroke recovery and consider stringent phenotyping to enrich the information captured to unveil additional 
stroke outcome loci. 
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INTRODUCTION 
 
 Ischemic stroke (IS) is the leading cause of adult disability1 and the second cause of death 
worldwide.2 Approximately 15 million people per year have a stroke, five million result in long-term 
disability.3 More than a thousand potential targets for neuronal recovery have been identified,4 although 
few have been tested in clinical trials. As no trials had positive results it is of high priority to find new 
drug targets for clinical practice. 
 
Functional outcome after IS varies between individuals irrespective of clinical factors as initial 
stroke severity, stroke subtype, and vascular risk factors.5 Multiple metabolic pathways are important in 
the response to cerebral ischemic damage and their activity may be modulated by variation in the genes of 
the involved components. New synaptic connections have been observed in areas surrounding a cerebral 
infarct within days following a stroke and this response is correlated with functional recovery.6 
 
It is reasonable to presume that genetic variation may influence stroke recovery.7 Candidate-gene 
studies reported the association between several genes and disability after stroke, but no locus has been 
found through a hypothesis-free genome-wide approach and most of the reported candidates failed to 
replicate in other cohorts.8 
Genome-wide association studies (GWAS) have identified multiple single nucleotide 
polymorphisms (SNPs) contributing with a small effect to the risk of complex diseases, and different 
genes have arisen as potential therapeutic targets to reduce the risk of stroke.9,10 Studying the genetic 
component of stroke outcome is of great scientific interest but requires very accurate phenotyping and 
proper attention to potentially confounding factors that may hide the true genetic contribution. 
 
We aimed to find the genetics influencing the stroke recovery process in a dataset of first-ever IS 
patients, using highly accurate phenotyping and producing the largest GWAS in stroke mid-term 
functional outcome to date to identify new potential drug targets. 
 
 
 
METHODS 
 
The data that support the findings of this study are available from the corresponding author upon 
reasonable request. 
Detailed Methods are provided in the Supplement. 
Study design. 
We conducted a two-phase analysis; discovery-replication and joint association of IS cases. The discovery 
consisted of a meta-analysis of four GWAS. The replication was performed as an in silico analysis of the 
top SNPs (p<1x10-5) identified in the discovery. Two final joint meta-analyses according to open or 
stringent criteria were performed. The open joint meta-analysis (n=2,482) included four discovery and 
eight replication cohorts and the stringent joint meta-analysis (n=1,791) four discovery and three 
replication cohorts. This joint approach has proved to be more efficient than discovery-replication alone 
in increasing the statistical power.11 A gene-based burden test was conducted. 
 
Study sample. 
European ancestry patients with a diagnosis of IS according to World Health Organization criteria were 
selected from the Spanish Stroke Genetics Consortium (GeneStroke) and the International Stroke 
Genetics Consortium. 
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Genome-wide association study. 
After GWAS quality controls and imputation, association analyses with 3-month mRS were performed 
using an additive model and a multivariate linear regression. The common variants between the individual 
GWAS were joined into weighted z-score meta-analyses for 3-month mRS. All the SNPs with p<5x10-8 
were considered statistically significant for a genome-wide approach. 
 
 
 
RESULTS 
 
Genome-wide association study. 
 
GWAS – Discovery phase: We meta-analyzed four individual GWAS with 1,225 individuals and 
4,480,015 SNPs in the discovery phase. In the bivariate analysis (Online Table II), 3-month mRS showed 
association with age at stroke onset, sex, smoking status, stroke subtype by Trial of Org 10172 in Acute 
Stroke Treatment (TOAST),12 and discharge NIHSS. The results include 79 variants in 18 independent 
(r2<0·001) genomic regions associated with impaired 3-month mRS at p<1×10−5 (Figure 1, Online Table 
III), selected for replication. Global genomic inflation was λ=1·032. Best evidence was for three SNPs in 
PATJ on chromosome 1 exceeding p<5x10-8: rs76221407 (p=1·087x10-8, beta=0·42); rs150862264 
(p=1·539x10-8, beta=0·41); and rs182008837 (p=1·825x10-8, beta=0·40). The top variant was imputed 
with r2=89·9% and imputation certainty=99·2%. 
 
GWAS – Replication phase: The SNPs selected for replication were analyzed in eight cohorts (Online 
Table IV). The stringent replication meta-analysis with three cohorts that strictly fulfil our selection 
criteria showed five SNPs in PATJ nominally associated with 3-month mRS (p<0·05), including the three 
top SNPs from the discovery (Online Table V). The effect size in the replication is slightly lower than in 
the discovery, indicating widespread consistency of results among the cohorts. 
 
GWAS – Joint: A stringent joint meta-analysis was performed with the four discovery and the three 
stringent replication cohorts (1,791 individuals). The analysis revealed strong genetic association between 
18 low frequency SNPs in PATJ and worse 3-month mRS (Table 1). The most striking SNP was 
rs76221407 (p=1·72x10-9, beta=0·40), as shown in the forest plot (Online Figure IV), driven by a variant 
with low frequency (3%) in our European ancestry cohorts (which is consistent with 1KG data). Figure 3 
shows the percentage of patients per group of 3-month mRS depending on the presence of the risk allele. 
An open joint meta-analysis was performed with all 12 cohorts (2,482 individuals) independently of 
meeting criteria for stringent analysis. Results revealed less significant p-values than the stringent 
analysis (rs76221407, p=1·3x10-8, beta=0·37) (Figure 2, Online Table VI, Online Figure V). The % of the 
phenotypic variation in 3-month mRS accounted by the lead SNP is 0·27% in the whole sample (12 
cohorts). 
 
The same analyses through an ordinal regression showed loss of statistical power (stringent 
p=3·60x10-5; open p=4·33x10-5). Evidence of the robustness of the genetic association presented in this 
work is clearly shown in Figure 2, where the top SNP has a consistent effect direction in 11 out of 12 
cohorts. 
 
Gene-based study. 
 
The gene-based association test revealed the PATJ gene as significantly associated with 3-month 
mRS. The 4·48 million genetic variants from the discovery GWAS were clustered in 23,972 genes, of 
which the only significant gene was PATJ (p=1·99x10−6) (Online Table VII). Significance threshold was 
set at p<0·05/23,972=2·086x10−6. 
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DISCUSSION 
 
We report the first genetic findings in IS outcome using a GWAS. Our results show a novel 
association between low frequency genetic variants in PATJ gene and worse IS functional outcome 
measured with 3-month mRS. Genetic studies on IS outcome had previously focused on candidate loci 
(see Lindgren & Maguire).7 However, findings had shown contradictory results and failed in consistent 
replications.8 We performed a meta-analysis of 12 independent cohorts within the International Stroke 
Genetics Consortium, applying open and stringent criteria. Several low frequency variants in PATJ were 
significantly associated with worse functional outcome at 3-months. The lead variant, rs76221407, 
presents a consistent effect direction in 11 of 12 cohorts, providing convincing evidence of its robust 
genetic association with stroke outcome. The SNP is located in an intronic region of PATJ and shows LD 
with 17 other variants found through the stringent joint meta-analysis (r2>0·3, in 1000 Genomes Project 
for European ancestry individuals). The fact that the variants are intronic may suggest that its effect on 
protein synthesis is carried out through the regulation of gene expression, similar to other common 
variants identified by GWAS that are linked to diseases by their modulation of the activity of DNA 
regulatory elements.13 No previously established risk locus for stroke10 has been related to stroke outcome 
in this work. Considering our restrictive inclusion criteria, which widely differ from the case/control 
studies, it is reasonable that we do not find overlaps in the top SNPs. None of our significant variants 
have been associated with another phenotype yet, although other PATJ polymorphisms have been related 
to sleep disturbance14 and obesity-related traits.15 
 
The results show a positive effect (beta=0·4) for the G allele of rs76221407, indicating that an 
increase of 0·4 points in the mRS score is attributed to each copy of G allele (GG>GA>AA). This means 
that G allele is related to poor functional outcome at 3-month. The results from the gene-based test also 
revealed significance for this locus (p=1·99x10-6) pointing out PATJ as a hot region of accumulated 
contributing variants. Although our PATJ SNPs are low frequency (~3%), the power of the association is 
strong enough to persist in the replication, evidencing the consistency of the results presented and the 
suitability of this gene as a therapeutic target. 
 
PATJ, localized at tight junctions and at the apical membrane of epithelial cells, encodes a protein 
with seven PDZ domains, interaction modules that regulate multiple biological processes like ion channel 
signaling and transport. 
 
In order to study the genetic component of a complex trait as IS functional outcome, it is key to 
be precise in characterizing the phenotype. The exclusion of posterior and lacunar strokes was considered 
necessary because these locations show a poor correlation between infarct size and clinical symptoms, 
and thus functional outcome.16 A small lesion can be asymptomatic or show very severe symptoms with 
great disability depending on a variation of just few millimeters in its location. In these cases, recovery 
processes and tissue regeneration mechanisms could be masked by this random location effect. 
 
Minor strokes (initial NIHSS≤4) and individuals with a dependent status previous to the stroke 
event (mRS>2) were also excluded. This was done to permit the analyses of an equivalent recovery 
process, without taking into consideration the degree of disability before stroke or those patients with 
only minimal damage to be recovered. In both cases, it would be difficult to evaluate the significance of 
recovery at 3-month. The achievement of a highly homogeneous sample was one of the main priorities 
during the study design. This led to the performance of two types of joint meta-analyses. The more 
permissive inclusion criteria of the open analysis led to a larger sample size (1·5 times greater) but less 
significant results compared to the stringent analysis. The reduction of phenotypic heterogeneity by 
properly defining the study cohort increases statistical power.17 While the phenotypic homogeneity of the 
sample is the main strength of our study, it also limited the sample size, as very few cohorts worldwide 
have the complete data needed for the stringent analysis8 and this may prevent the discovery of other loci. 
 DOI: 10.1161/CIRCRESAHA.118.313533   7 
However, our work demonstrates the value of prioritizing homogeneity and phenotyping accuracy over a 
larger sample size. The mRS, the most widely used scale in stroke patients to assess functional outcome, 
has only seven categories but it offers the advantages of being easy to apply and having good inter-
observer reproducibility.18 Analyzing the mRS score as a continuous instead of an ordinal value,19 
according to Rhemtulla et al, is the preferable choice for ordinal data with more than four categories in 
contrast to robust categorical methodology,20 and the statistical power is improved. 
 
This project generated extensive genotyping and phenotyping of individual-level data that can 
help to disentangle the genetic architecture of the stroke recovery process. The use of whole exome or 
genome sequencing would provide information about rare variants, which may account for a greater 
proportion of the stroke outcome’s genetic component than common variants. Additional functional 
studies are warranted to establish whether PATJ can reveal biological pathways that could be novel 
therapeutic targets to improve post-IS rehabilitation strategies. 
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SNP Position Gene SNP type MA MAF Beta Beta (80% power) SE p 
rs76221407 1:62131826 PATJ intronic G 0·03 0·40 0·44 0·07 1·72x10-9 
rs150862264 1:62132045 PATJ intronic C 0·03 0·40 0·44 0·07 1·76x10-9 
rs182008837 1:62107102 PATJ intronic C 0·03 0·39 0·43 0·07 2·93x10-9 
rs117335978 1:62140649 PATJ intronic T 0·02 0·46 0·54 0·08 1·96x10-8 
rs137999692 1:62092932 PATJ intronic A 0·03 0·36 0·43 0·07 2·98x10-8 
rs75717958 1:62141064 PATJ intronic A 0·02 0·47 0·55 0·08 3·71x10-8 
rs7546744 1:62141462 PATJ intronic A 0·02 0·47 0·55 0·08 3·71x10-8 
rs7513982 1:62141944 PATJ intronic C 0·02 0·47 0·55 0·08 3·72x10-8 
rs17123133 1:62142178 PATJ intronic A 0·02 0·47 0·55 0·08 3·72x10-8 
rs7514107 1:62142096 PATJ intronic C 0·02 0·47 0·55 0·08 3·72x10-8 
rs141479296 1:62140561 PATJ intronic G 0·02 0·47 0·55 0·08 3·77x10-8 
rs11805802 1:62142912 PATJ intronic C 0·02 0·47 0·55 0·08 3·78x10-8 
rs10157504 1:62140248 PATJ intronic G 0·02 0·47 0·55 0·08 3·80x10-8 
rs74469018 1:62144275 PATJ intronic T 0·02 0·47 0·56 0·08 3·86x10-8 
rs77007585 1:62144350 PATJ intronic A 0·02 0·47 0·56 0·08 3·88x10-8 
rs11806656 1:62144566 PATJ intronic C 0·02 0·47 0·56 0·08 3·88x10-8 
rs7542598 1:62145477 PATJ intronic T 0·02 0·47 0·56 0·08 3·95x10-8 
rs118168181 1:62141702 PATJ intronic A 0·02 0·47 0·56 0·09 3·98x10-8 
 
 
Table 1: Intronic variants in PATJ associated with 3-month mRS at p<5x10-8 in the stringent joint-
analysis 
SNP, single nucleotide polymorphism; Position, chromosome: genomic coordinates according to human 
genome reference version 19 (build GRCh38/hg38); MA, minor allele; MAF, minor allele frequency; 
Beta, beta value for the association; Beta (80% power), beta that could be detected as statistically 
significant under 80% power; SE, standard error; p, p-value. 
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FIGURE LEGENDS 
 
Figure 1: Manhattan plot (A) and Q-Q Plot (B) of the discovery results. Association testing was 
performed using a lineal regression model adjusted for the first two PCs, sex, age, smoking, stroke 
subtype, and discharge NIHSS. The red line shows p=1×10−5 and the blue line the GWAS significance 
threshold (p=5x10-8) (A). The X-axis is the expected −log10 p under the null hypothesis and lambda is the 
observed median χ2 test statistic divided by the median expected χ2 test statistic under the null hypothesis 
(B). 
 
Figure 2: Forest plot (A) and regional association plot (B) for rs76221407 in the open joint-analysis. 
Plot of the effect size of the association with 3-month mRS across the 12 cohorts (open joint-analysis) 
(A). Association of rs76221407 and other SNPs in the region was plotted with −log10 p-values (left y-
axis), the estimated local recombination rate in blue (right y-axis). The signals are distinguished by color 
and shape. Linkage disequilibrium (r2) of nearby SNPs is shown by color gradient (B). 
 
Figure 3: Distribution of 3-month mRS score in the stringent joint-analysis. *Joining in the same 
category the mRS values 5-6 and in the same group the G allele carriers (heterozygous and homozygous) 
is uniquely suited for facilitating the visualization of this figure, although the analyses are done without 
joining these categories. 
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NOVELTY AND SIGNIFICANCE 
 
 
What Is Known? 
 
 Disability due to stroke has a significant impact on public health as it affects the quality of life of 
both – the patients and the caregivers. 
 
 Irrespective of clinical factors, functional recovery after ischemic stroke (IS) varies widely 
among individuals. 
 
 Variability in functional outcome has been attributed, in part, to genetic factors, but to date, no 
locus has been consistently associated with stroke outcome. 
 
What New Information Does This Article Contribute? 
 
 Genetic variants in PATJ gene are associated with IS functional outcome at 3 months. 
 
 Association of PATJ gene variants with IS functional outcome was discovered through a meta-
analysis of genome-wide association studies (GWAS) and was validated in a multiple-cohort 
replication study. 
 
Cerebrovascular disease is the leading cause of adult disability. Mid-term functional recovery after stroke 
varies significantly among individuals, independent of infarct size, stroke subtype, vascular risk factors, 
or clinical status after acute treatment. Identifying genetic factors that contribute to this variability 
requires a hypothesis-free, comprehensive genotyping approach, such as GWAS, as well as accurate 
phenotyping to identify confounding factors that may obscure the genetic effects. Using a restrictive 
inclusion criteria to obtain a less heterogeneous patient population, in a multi-cohort GWAS we found 
that  PATJ gene variants were associated with functional outcomes in patients with IS. The accumulation 
of risk alleles in the PATJ gene was associated with a worse functional outcome at 3-month after IS. This 
evidence for a genetic contribution to mid-term stroke prognosis, provides a new platform for 
understanding the mechanisms that determine functional recovery after stroke, and may also help in  
better prediction of functional outcomes after IS. 
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